{"contentid": 488137, "importid": NaN, "name": "Pfizer takes aim at coronavirus and vaccines market", "introduction": "Pfizer, a leading developer of coronavirus vaccines, has made progress in a novel oral antiviral for the disease.", "content": "<p><span style=\"font-weight: 400;\">Pfizer (NYSE: PFE), a leading developer of coronavirus vaccines, has made progress in a novel oral antiviral for the disease.</span></p>\n<p><span style=\"font-weight: 400;\">The firm has also announced plans to use its experience developing mRNA-based vaccines to become a major force in the broader vaccines market.</span></p>\n<p><span style=\"font-weight: 400;\">In a statement, the New York-based pharma giant said it was progressing to multiple ascending doses in a Phase I study of its antiviral candidate PF-07321332.</span></p>\n<p><span style=\"font-weight: 400;\">The protease inhibitor has demonstrated potent in vitro antiviral activity against SARS-CoV-2, suggesting potential for use in the treatment of COVID-19.</span></p>\n<p><span style=\"font-weight: 400;\">Of particular interest is the fact that the candidate has shown activity against other coronaviruses, suggesting that it could be effective against variants of the disease.</span></p>\n<h2><strong>Launching pad</strong></h2>\n<p><span style=\"font-weight: 400;\">Pfizer is also working on an intravenous antiviral candidate, and believes that the two products could create an &ldquo;end to end&rdquo; range of treatments to complement vaccines.</span></p>\n<p><span style=\"font-weight: 400;\">Commenting on the latest trial developments, chief scientific officer Mikael Dolsten said: &ldquo;Tackling the COVID-19 pandemic requires both prevention via vaccine and targeted treatment for those who contract the virus.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">He added: &ldquo;Given the way that SARS-CoV-2 is mutating and the continued global impact of COVID-19, it appears likely that it will be critical to have access to therapeutic options both now and beyond the pandemic.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">In collaboration with German firm BioNTech (Nasdaq: BNTX), Pfizer has already led the way in the development of a safe and effective vaccine for the novel coronavirus, with the firms&rsquo; mRNA-based shot Comirnaty being rolled out across the globe.</span></p>\n<p><span style=\"font-weight: 400;\">Building on this success, chief executive Albert Bourla said his firm plans to work on more vaccines using mRNA technology, aiming to compete with established vaccines giants such as GlaxoSmithKline (LSE: GSK) and Sanofi (Euronext: SAN).</span></p>\n<p><span style=\"font-weight: 400;\">In an </span><a href=\"https://www.wsj.com/articles/pfizer-goes-it-alone-to-expand-vaccine-business-beyond-covid-19-pandemic-11616491800\"><span style=\"font-weight: 400;\">interview</span></a><span style=\"font-weight: 400;\"> with the Wall Street Journal, he said the technology had &ldquo;proven dramatic impact and dramatic potential,&rdquo; adding that Pfizer was the &ldquo;best positioned company right now to take it to the next step.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">Towards this end, Mr Bourla said his firm would leverage the infrastructure it has built up as a part of its collaboration with BioNTech, and hire at least 50 new experts in the technology to keep working on new candidates.</span></p>", "date": "2021-03-24 11:56:00", "meta_title": NaN, "meta_keywords": "vaccines, Pfizer, antiviral, coronavirus, firm, disease, candidate, COVID-, market, leading, developer, progress, oral, technology, suggesting, activity", "meta_description": "Pfizer, a leading developer of coronavirus vaccines, has made progress in a novel oral antiviral for the disease.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-24 11:24:57", "updated": "2021-03-24 11:57:23", "access": NaN, "url": "https://www.thepharmaletter.com/article/pfizer-takes-aim-at-coronavirus-and-vaccines-market", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "pfizer_colour_new_large.png", "image2id": "pfizer_colour_new_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Anti-virals, Infectious diseases, Vaccines", "topic_tag": "Drug Trial, Management, Research", "geography_tag": "USA", "company_tag": "Pfizer", "drug_tag": "Comirnaty, PF-07321332", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-24 11:56:00"}